Abstract Calcium plus vitamin D (CaD) supplementation has a modest but significant effect on slowing loss of femoral bone mass and reducing risk of hip fractures in adherent postmenopausal women. The goal of this study was to determine if CaD supplementation influences hip structural parameters that are associated with fracture risk. We studied 1,970 postmenopausal women enrolled in the Women's Health Initiative randomized controlled trial of CaD at one of three bone mineral density (BMD) clinical centers. Hip structural analysis software measured BMD and strength parameters on DXA scans at three regions: femoral narrow neck, intertrochanter, and shaft. Random effects models were used to test the average differences in hip BMD and geometry between intervention and placebo. There was greater preservation of hip BMD at the narrow neck with CaD relative to placebo across 6 years of intervention. CaD also altered the underlying crosssectional geometry at the narrow neck in the direction of greater strength, with small increases in cross-sectional area and section modulus and a decrease in buckling ratio with CaD relative to placebo. While trends at both the intertrochanter and shaft regions were similar to those noted at the narrow neck, no significant intervention effects were evident. There was no significant interaction of CaD and age or baseline calcium levels for hip structural properties. CaD supplementation is associated with modest beneficial effects on hip structural features at the narrow neck, which may explain some of the benefit of CaD in reducing hip fracture risk.
Keywords Calcium and vitamin D supplementation Á Bone strength Á Postmenopausal women Á Hip structure Osteoporosis is a major public health problem [1] . Fractures are the primary clinical consequence of osteoporosis, and four out of 10 women will suffer a fracture after the age of 50 [2] . Hip fractures are the most serious outcome of osteoporosis and one of the most disabling consequences of aging in women [3, 4] . Of those women who suffer a hip fracture, 10-45% will die within the year following their fracture [5] . In order to reduce the burden of this common condition, efforts have focused on identifying interventions that might reduce the population-based risk.
Calcium and vitamin D are nutritional factors being studied in fracture intervention studies as many segments of the U.S. population, including older women, are consuming inadequate dietary amounts of calcium and vitamin D. The results of studies exploring the effects of calcium plus vitamin D (CaD) supplementation on reduction of hip and total fractures have been mixed [6] . The Women's Health Initiative (WHI) randomized, controlled clinical trial of CaD supplementation demonstrated a nonstatistically significant 12% reduction in hip fractures with no effect of CaD on wrist, clinical vertebral, or total fractures. In subgroup analyses, however, a significant 21% decrease in hip fractures was noted for women over age 60 and a 29% reduction was noted in adherent women [7] . Several recent meta-analyses are consistent with the above findings and suggest modest benefits of CaD on bone mineral density (BMD) and fractures, particularly with calcium intakes over 1,200 mg and with vitamin D supplementation greater than 800 units daily [6] .
CaD may act through several pathways to reduce the risk for hip fracture, including reducing the risk for falling [8] [9] [10] [11] [12] [13] [14] [15] , having positive effects on calcium balance [12, 16] ; reducing bone resorption through modifying parathyroid hormone secretion [12, 17, 18] , and preserving BMD [7, 12, 19] . However, BMD is a limited surrogate marker for improvements in bone strength as it does not express the measured mineral in a nonambiguous format that can be interpreted mechanically [20] .
Recent studies have suggested that therapeutic interventions that reduce fracture risk, such as estrogen, raloxifene, or bisphosphonates, may improve the structural geometric properties of the proximal femur [21] [22] [23] [24] [25] . These structural properties can be estimated from analyses of hip scans using dual-energy X-ray absorptiometry (DXA) [26, 27] , and differences in structural properties have been found between fracture cases and controls [28, 29] . Recently, a study among the participants in the WHI demonstrated an independent contribution of hip structural parameters from bone density to the risk of hip fracture [30] , providing evidence of the importance of having both material and structural measures in examining fracture risk and mechanisms for fracture risk reduction.
The purpose of the current study was to use data from the BMD subcohort of women enrolled in the WHI randomized, controlled clinical trial of CaD supplementation to examine the hypothesis that CaD supplementation has a beneficial effect on hip structural geometry. We further hypothesize that the effects of CaD on hip structure will be greater in older women consistent with the greater effect of CaD on hip fracture among women over 60 in the WHI.
Methods
The Women's Health Initiative Study
The WHI was a large study designed to address major causes of death and disability in older postmenopausal women. It included a combination of four nested clinical trials and an observational study designed to investigate whether hormone therapy (estrogen alone or estrogen plus progestin), low-fat diet, and/or CaD supplements reduced the risk of major conditions in older women including heart attack and stroke, breast and colorectal cancers, and osteoporotic fracture. Postmenopausal women aged 50-79 years who were not likely to change residence and had no evidence of a medical condition associated with predicted survival of less than 3 years at the time of enrollment were recruited from 40 clinical centers nationwide between 1993 and 1998. All participants provided written consent to participate in the WHI. Details regarding the inclusion and exclusion criteria, recruitment procedures, participant characteristics, randomization, blinding, and follow-up have been previously published [31, 32] . The University of Arizona's Institutional Review Board approved this project.
WHI CaD Trial
The WHI CaD trial was a randomized, double-blind, placebo-controlled clinical trial of calcium (1,000 mg elemental calcium in the form of calcium carbonate) with 400 units of vitamin D 3 (cholecalciferol) in divided daily doses versus placebo. Participants who were enrolled in the WHI low-fat Dietary Modification trial, one of the WHI Hormone Therapy trials, or both were recruited into the CaD trial at their first or second annual follow-up visit (n = 36,281). The primary outcome of the CaD trial was hip fracture; total fractures and colorectal cancer were prespecified secondary outcomes. The trial was designed to last for an average of 7.0 years of follow-up.
Questionnaires were used at baseline and follow-up to collect information on demographics, lifestyle and health behavioral factors, and clinical risk factors for osteoporotic fracture. Total daily calcium intake was defined as the sum of the dietary calcium intake assessed by the use of a modification of the Block food-frequency questionnaire [33] , intake of CaD supplements in the previous 2 weeks, and intake of calcium from prescription medications. Total vitamin D intake was similarly assessed.
A subgroup of 2,350 women (1,179 in the CaD group and 1,171 in the placebo group) at three of the 40 clinical centers (Pittsburgh, PA; Birmingham, AL; and Tucson/ Phoenix, AZ), chosen to maximize racial diversity, underwent DXA scans (QDR 2000, 2000?, or 4500 W; Hologic, Waltham MA) of the spine (L2-L4), hip, and total body. This DXA subgroup became the cohort used for the analysis of hip structural geometry.
BMD was measured at the CaD randomization visit and at annual visits 3 and 6 according to standard protocols [32] . Three Hologic phantoms were exchanged among the DXA centers and measured in array mode five times, one each day for five consecutive days to assess crosscalibration. Spine, hip, and linearity phantoms were in close agreement as previously described. For hip structural geometric measurements, a separate cross-calibration was conducted using a special phantom (provided by T. J. B. from Johns Hopkins University).
Hip Structural Analysis
Hip structural analysis (HSA) was conducted on archived scans at the Johns Hopkins University as previously described [26, 27] . The HSA program computes geometry from five parallel lines, 1 pixel (*1 mm) apart, traversing the bone axis at each of three femoral cross sections: narrow neck, across the femoral neck at its narrowest point; shaft, across the shaft at a distance of 1.5 times minimum neck width distal to the intersection of the neck and shaft axes; and intertrochanter, along the bisector of the angle produced by the neck and shaft axes.
HSA is based upon the concept that a line of pixel values in a bone mass image is a projection of the mineral in the corresponding cross section [34] . Assuming that the mineral is distributed as it is in adult cortical bone, the profile integral is a measure of the total bone surface, thus its resistance to axially directed loads. The distribution of the mineral along the profile, after correcting for mineralization, is used to derive the cross-sectional moment of inertia (CSMI) for resisting bending in the image plane. The CSMI can be used to evaluate bending stress at any point within the cross section. The maximum bending stress, defined at the surface farthest from the center of mass (d max ), is inversely related to the section modulus, computed as CSMI/d max . An estimate of buckling ratio is generated as an index of susceptibility to local cortical buckling under loads that produce compression. Wall thickness for a buckling ratio can only be crudely estimated from DXA data using assumptions of shape and the proportion of measured bone in the cortex, but this parameter has been shown to provide a mechanical explanation for the predictive value of low BMD in elderly bones [28, 29] . The HSA program also computes conventional BMD, bone outer diameter, as well as other parameters not used in the present study
Statistical Analysis
Descriptive analyses and group comparisons (t-test for continuous variables, chi-squared test for categorical variables) were conducted by intervention group for selected characteristics of the study participants at baseline. The intention-to-treat principle was used in the analyses to test CaD intervention effects on BMD and hip structural geometric measurements. The mean BMD and hip geometric measurements were compared cross-sectionally by treatment group at each time point (baseline, year 3, and year 6). Intervention effects of CaD were first examined by testing the differences in percent of changes from baseline to year 6 for BMD and the hip structural geometric measurements between the placebo and the CaD intervention groups using linear regression models. Then, a random effects model (REM), a type of linear mixed effects model which uses all observations at different time points in a cohort study, was used to test the average differences in hip BMD and geometry between intervention and placebo groups. In addition, any temporal differences (differences in the slope over time) between the two groups were examined using REM. In evaluating potential confounding factors and interaction terms, models examined baseline age (continuous and dichotomized at age [60), height, ethnicity, whole-body BMC, whole-body bone area, percent lean mass, physical activity, baseline hormone use, and hormone therapy (HT) trial randomization. Marginal analyses were used to evaluate each covariate separately; then, variables with P \ 0.2 were examined in the models with other covariates. Backward selection techniques were used to remove covariates and finalize the model. Subgroup analyses examining the interaction of the intervention with age, baseline calcium intake, and trial adherence were performed. Predicted values normalized to baseline were used to graphically portray the results of the final REM models. STATA v.10 (StataCorp, College Station, TX) was used for all data analyses.
Results

Baseline Characteristics
Out of 2,350 women in the CaD trial who were in the DXA cohort, a total of 1,970 (991 in the CaD group and 979 in the placebo group) completed at least two hip DXA scans and were included in the hip geometry analyses. Demographic characteristics, health behaviors, and medical history were well balanced between the groups (Table 1) . These women had a mean (SD) age of 62.0 (7.1) and a mean body mass index of 28.8 (5.5) kg/m 2 . The average total daily calcium intake was approximately 1,044.1 mg, and one-third were currently using HT (320 [32.7%] in the placebo group and 304 [30.7%] in the CaD intervention group). Baseline total-body, hip, and spine BMD values were modestly but significantly higher in the CaD intervention vs. placebo group. Three femoral geometric properties, cross-sectional area, section modulus, and buckling ratio, also differed between the CaD and placebo groups at baseline ( Table 2 ).
Changes in BMD and Hip Geometry due to Intervention
There was greater preservation of hip BMD at the femoral narrow neck with CaD relative to placebo across 5 years of intervention; no significant effect of CaD was noted at either the intertrochanter or femoral shaft (Fig. 1) . The BMD effect at the narrow neck was seen as early as annual visit 3, 2 years after CaD randomization, and persisted through annual visit 6 (Fig. 2) .
CaD also altered the underlying femoral cross-sectional geometry at the narrow neck in the direction of greater strength. When comparing the percent difference between baseline and year 6, cross-sectional area significantly increased relative to placebo (P \ 0.05) at the narrow neck (Fig. 1) . No benefit was evident for the outer diameter, buckling ratio, or section modulus. In contrast to the narrow neck region, there were no significant effects of CaD at the intertrochanteric and femoral shaft regions for any of the geometric properties measured.
Longitudinal Analysis on Intervention Effects
The effects of CaD supplementation over time based on the REM are shown in Table 3 . From the baseline CaD enrollment visit to annual visit 3 (2-year interval), small increases in BMD, cross-sectional area, and section modulus and a decrease in buckling ratio at the narrow neck were seen with CaD relative to placebo in the crude and adjusted models. The results did not change when the model was fully adjusted for age, ethnicity, HT use, percent lean body mass, and WHI-CT assignment in addition to the baseline value, height, and weight (data not shown). By annual visit 6, there was a subsequent loss of some of the gains between baseline and annual visit 3 for all geometric properties, with the exception of outer diameter, with no evidence of significant differences in the rates of gain (or loss) over time between the placebo and CaD intervention groups (Fig. 2) . Even with minor loss of the benefit gained, based on the REM, CaD intervention provided a small, yet statistically significant, improvement in bone strength. While trends at both the intertrochanteric and femoral shaft regions were similar to those noted at the narrow neck, no significant longitudinal effects of CaD intervention on BMD and hip geometry at these two other regions were evident (data not shown).
Subgroup Analyses of Intervention Effects
Although the effect of CaD on hip fracture varied with age, reaching a significant 21% decrease in risk for women [60 years of age in the WHI CaD trial, there was no significant interaction of CaD and age for hip structural properties (data not shown). There was also no difference in the effects of CaD based on reported baseline dietary and supplemental calcium intake levels.
Participants with 80% or greater compliance with the study protocol were considered adherent. A total of 968 women (CaD placebo = 500, CaD intervention = 468) were adherent throughout the 5 years of examination. Slightly stronger CaD effects were seen in this population, especially in the intertrochanteric and shaft regions, although the overall results of the adherence analyses were similar to the entire cohort (data not shown).
Discussion
CaD has been shown to reduce the risk of hip fracture in older postmenopausal women [6] . In this prospective randomized controlled trial of CaD supplementation, the previously demonstrated improvement in hip BMD relative to placebo was seen at the narrow neck, with a nonsignificant trend toward improvement in BMD at the intertrochanteric and femoral shaft regions of the proximal femur.
The ability of the hip to withstand the force of fracture should be directly evident in cross-sectional geometry. Applying HSA to DXA to explore the mechanical implications of CaD in this study revealed limited effects of CaD on measurements of femoral geometric properties in crude and adjusted models. Over the follow-up period, BMD and geometric properties of cross-sectional area and section modulus increased significantly at the narrow neck, consistent with greater strength. Similarly, with CaD intervention, buckling ratio significantly decreased over the 6 years.
Overall, there were no detectable benefits of CaD on geometric properties at either the intertrochanteric or femoral shaft region. The lack of a statistically significant effect at these other hip regions differs from the improved effects noted at all three HSA regions with HT and alendronate [21, 22] . It should be noted that the magnitude of the treatment effect was greater in the latter studies. These results, however, are consistent with the reported lack of effect of CaD on reducing risk of fracture at other skeletal sites [7] ; thus, the lack of effect at the intertrochanteric and shaft regions could also reflect the difference in fracture risk reduction with CaD relative to the greater reduction of both vertebral and nonvertebral fractures reported with estrogen [35, 36] and alendronate [37, 38] . Previous studies have postulated that the generalized expansion of femoral diameter with aging helps to preserve bending resistance (section modulus) in the presence of net bone loss until this compensatory change can no longer overcome the concurrent effect of endosteal resorption, eventually resulting in cortical thinning and mechanical instability [39] . In a previous report using data from the same WHI subcohort, a significant independent contrition of femoral diameter at the intertrochanteric region to hip fracture risk was observed [30] . In this study, we demonstrate a modest but nonsignificant attenuation of outer diameter expansion with CaD and a small but significant reduction in buckling ratio. Lack of an apparent effect on buckling ratio at the intertrochanteric region reduces enthusiasm for the conclusion that CaD lowers susceptibility to local buckling. This is the first longitudinal study to examine HSA parameters derived from DXA in relation to CaD supplementation in older adults. In this study, the effects of CaD on geometric properties at the narrow neck correspond with an increase in bone strength at an important fracture site. Conceivably, tissue material strength may be improved by CaD treatment in ways that would not be evident in DXA measurements of geometry. Indeed, Boivin et al. [40] noted some increase in average tissue mineralization in iliac biopsies of women on estrogen therapy. This may be important since DXA-derived measurements of geometry by HSA assume a constant tissue mineralization. Thus, a net gain in mineralization with CaD may cause an overestimate in cross-sectional surface. This might suggest that the reported effect of CaD on CSA is actually more modest than suggested by the data in this study.
Hip fractures are more common with advancing age. In the WHI CaD trial, there was a significant interaction of age with CaD and, in women over 60 years, a 21% decrease in the risk of hip fractures with CaD. In contrast, however, there was no significant interaction of age and CaD on HSA geometry, suggesting that CaD has similar effects on bone strength for both older and younger postmenopausal women [29] .
One cannot exclude that the effect of CaD on hip structure might be more pronounced in a more calciumdeficient population, and this study examined the effects of CaD in postmenopausal women who had an average daily calcium intake prior to randomization that was close to calcium-replete. The lack of any significant interaction of the CaD effect with baseline calcium intake on changes in hip structural geometry, however, does not support this hypothesis. These results are also consistent with crosssectional data that demonstrate little effect of calcium intake on any of the HSA structural variables [41] .
Significant fracture reduction was found in the main CaD trial among the participants adherent to study treatment. Our analyses similarly demonstrate slightly stronger CaD treatment effects among the adherent women. The importance of the observation that the increase was more pronounced at the intertrochanteric and shaft regions compared to the narrow neck is unknown.
Strengths and Limitations
This study is the first prospective examination of CaD on hip strength in a multiethnic population of postmenopausal women. Strengths of the study include the longitudinal CaD intervention and serial BMD measurements over several years that allowed assessment for the hip geometric structural changes across time. In addition, the large sample size and carefully defined risk factors for fracture allowed for focused analyses to explore subgroups of women, based on age, baseline CaD intake, and adherence, who might demonstrate a greater impact of CaD on hip structure.
There are, however, some limitations to the study. The HSA method is not the most precise structural measurement, and several limitations have been noted including the precision of estimating three-dimensional structures from a two-dimensional measurement and uncertainties in consistent positioning of the femur [42] . One should also be cautious in differentiating between an effect that is not occurring and one that is occurring below the threshold of detectability. This could possibly explain the lack of interaction by age, which was seen in the main CaD and fracture study.
Other limitations include differences in the study population between the main CaD study. DXA scans were only performed in the subcohort of women participating in the BMD centers, so the balance in baseline characteristics between the placebo and CaD intervention groups was not completely maintained between studies. Also, the study participants in the CaD trial were at low clinical risk for fracture [7, 32] . These factors may be responsible for the low CaD effect seen on changes in hip structure.
Finally, there were significant differences in baseline BMD and several other HSA parameters between the placebo and the CaD supplementation groups at baseline. However, these differences were taken into account when computing the average effects of CaD on bone strength in the longitudinal modeling by adjusting for the baseline parameter. We observed an increased bone strength in both the placebo and the CaD supplement groups from baseline to the third-year visit of the follow-up, although the increase was much larger in the supplement group in comparison to the placebo group. There are no ready explanations for this increase in bone strength for the placebo group in the first 3 years of the CaD trial. However, this pattern of change in bone strength did not affect our ability to assess CaD effects at each visit or over the entire trial period since the relative differences between the placebo and the CaD supplementation groups are the focus of this analysis.
Conclusions
In summary, participants in the WHI CaD trial were healthy postmenopausal women with few risk factors for fracture who were close to being calcium-replete at randomization into the trial. However, despite this, CaD supplementation is associated with modest beneficial effects on hip structural features at the femoral narrow neck. These data support a hypothesis that some of the benefit of CaD in reducing hip fracture risk may result from enhanced geometric properties that lead to improved bone strength. Table 3 Longitudinal effect of CaD supplementation on BMD and hip structural geometry at the narrow neck region 
